VR funding to Ruth Palmer

Last updated on Nov 21, 2023 1 min read

The Swedish Reasearch Council (Vetenskapsrådet, VR) is granting Ruth Palmer 4.8 million SEK.

She recieves the funding for the project Exploring ALK downstream signaling for improved targeted therapies and future treatment of Neuroblastoma. The lab is now able to continue our work towards a molecule or set of molecules that when targeted kills off the tumor cells while leaving healthy tissue unaffected. While the lab has been able to, in the past, find treatment options for individual patients1 2, we are still looking to discover a therapy that is effective on an entire patient group.

  1. Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation ↩︎

  2. Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib

    Vetenskapsrådet
     ↩︎

Ruth Palmer
Ruth Palmer
Professor at Department of Biochemistry and Cell Biology

I want to impart those around me with my enthusiasm for research and to train the next generation scientist.